Hygieia Pharmaceuticals_MVIP_DDP

“

Discovering RNAi Values,

Revolutionizing Patient Care

BENEFIT PATIENTS TO BECOME A

NEW GENERATION OF SMALL NUCLEIC ACID DRUG BENCHMARKING ENTERPRISES

4

Clinical Programs

15 +

Research Pipeline

2018 Year

Company Start-up

Hygieia Pharmaceuticals Co., Ltd.

Hygieia Pharmaceuticals is committed to building a delivery technology platform and drug development of siRNA. We have established a complete end-to-end siRNA drug development platform from target discovery to clinical Proof of Concept (POC), and have a professional team with rich experience covering the entire life cycle from early research and development to industrialization.

LERAN MORE→

Technology Platform

R & D Pipeline

Hygieia Pharmaceuticals, is committed to develop innovative drugs with global competitive advantages, independently develops and promotes multiple differentiated pipelines. Our pipelines are primarily focused on liver diseases, cardiovascular and metabolic diseases, complement-mediated diseases, neurological diseases and other diseases with high unmet clinical needs.

LERAN MORE→

News

2025 AHA | Dose-Dependent and Sustained Reduction in Lipoprotein(a) Level after a Single Dose of Kylo-11, an LPA-targeted Small Interfering RNA, in Healthy Volunteers: A First-in-Human Phase I Study

2025-11-11

HANGZHOU, China – November [11], 2025 – Hygieia Pharmaceuticals (referring to “Hygieia” thereafter), a clinical-stage biotech company dedicated to developing RNAi medicines, today announced that the preliminary results from the first-in-human Phase I study (NCT06363851) of Kylo-11 (an experimental small interfering RNA medicine targeting LPA mRNA) in healthy volunteers with elevated serum Lp(a) level. The data were presented in an oral presentation at the American Heart Association (AHA) Scientific Sessions in New Orleans, Louisiana (Abstract ID: 4390197).

LERAN MORE→

Hygieia Pharmaceuticals Announces First Patient dosed in a US/CN Multi-Center Phase II Clinical Trial Investigating a Long-acting Small Interfering RNA (siRNA) Therapy (Kylo-11) Designed to Lower the Production of Lipoprotein(a) [Lp(a)]

2025-10-30

HANGZHOU, China – October [30], 2025 – Hygieia Pharmaceuticals (“Hygieia”, or the “Company”), a clinical-stage biopharmaceutical company today announces that the first patient has been dosed at Peking University First Hospital in an international US/CN multi-center Phase II clinical trial investigating Kylo-11, a small interfering RNA (siRNA) program designed to lower serum lipoprotein(a) [Lp(a)], an important risk factor for cardiovascular diseases. This study will be conducted in both China and the United States.

LERAN MORE→